Health Dictionary Find a Doctor

Pituitary apoplexy

For patient information, click here

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Akshun Kalia M.B.B.S.[2]Sargun Singh Walia M.B.B.S.[3]

Synonyms and keywords: pituitary gland infarction; pituitary infarct; pituitary hemorrhage; pitutary apoplexy

Overview

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Akshun Kalia M.B.B.S.[2]

Overview

Pituitary apoplexy is caused by hemorrhage into the pituitary gland. The pituitary gland is a small gland joined to the hypothalamus at the base of brain. The pituitary produces many of the hormones that control essential body processes. Pituitary apoplexy is most commonly associated with pituitary adenoma. The common symptoms of pituitary apoplexy are severe headache with nausea and vomiting. Other symptoms depends upon the amount of hemorrhage and necrosis in the pituitary gland. Hemorrhage into the pituitary gland may compress the surrounding structures and present with ophthlamoplegia, cranial nerve palsies, and signs of increased intracranial pressure. The initial diagnostic test is a CT scan without contrast which will show the hemorrhage as a hyperintense lesion. In the case of inconclusive CT, an MRI may be done to better visualize the lesion. Laboratory tests are done to identify specific hormone and electrolyte disturbances. The initial management of pituitary apoplexy includes rapid hemodynamic stabilization of the patient with replacement of hormones. Depending upon the patient’s condition after initial management, neurological decompression may be done.[1][2]

Historical Perspective

Pituitary apoplexy was first discovered by Pearce Bailey in the year 1898. In 1905, Leopold Bleibtreu recorded the postmortem examination of a 21-year-old acromegalic patient, in whom he discovered that the pituitary gland had been replaced by an old hemorrhage. The term “pituitary apoplexy” was coined by Brougham, Heusner, and Adams in the year 1950.[3]

Pathophysiology

Pituitary apoplexy is an acute clinical syndrome caused by hemorrhage and necrosis in the pituitary gland. Most commonly, pituitary apoplexy is associated with pituitary adenoma. The pituitary adenoma predisposes the patient to an increased risk of bleeding within the pituitary gland. The pituitary adenoma has fenestrated endothelium surrounded by a variable number of smooth muscle cells, which are not found in the normal pituitary gland.Gene involved in the pathogenesis of pituitary apoplexy include a mutation in AIP gene, which is located on chromosome 11q13.2. On gross pathology, pituitary apoplexy presents with hemorrhage with or without necrosis. Electron microscopic shows evidence of abnormal fenestration of tumor vessels (pituitary adenoma) with fragmented basal membranes that may predispose the patient to hemorrhage.

Differentiating Pituitary apoplexy From Other Diseases

Pituitary apoplexy must be differentiated from other diseases that cause severe headache such as subarachnoid hemorrhage, meningitis, intracranial mass, cerebral hemorrhage, cerebral infarction, intracranial venous thrombosis, migraine, head injury, lymphocytic hypophysitis, and radiation injury.[4][5][6]

Epidemiology and Demographics

The worldwide prevalence of pituitary apoplexy is 6.2 per 100,000 persons. The incidence of pituitary apoplexy is 0.7 per 100,000 persons.[7]

Risk Factors

Common risk factors in the development of pituitary apoplexy include bleeding disorders, diabetes, use of a breathing machine, radiation to the pituitary gland, angiography, head injury, surgery, pituitary stimulation, and pregnancy induced lactotroph hyperplasia.[8]

Screening

There are no screening guidelines for pituitary apoplexy.

Natural History, Complications, and Prognosis

If left untreated, pituitary apoplexy is an acute life threatening condition. Pituitary apoplexy may lead to a sudden decline in pituitary hormone production. The most life threatening endocrinopathy is acute adrenal crisis. Complications of pituitary apoplexy include vision loss, optic neuritis, diplopia, ptosis, increased intracranial pressure, hypothyroidism, hypogonadism, and growth hormone deficiency. The prognosis of pituitary apoplexy depends upon presentation and initiation of therapy. Emergent application of medical and surgical treatment is associated with greater improvement in visual field defects, visual acuity, and diplopia. The outlook is good for people who are diagnosed early and treated. Patients require hormone(s) replacement therapy for life.[9]

Diagnosis

History and Symptoms

Pituitary apoplexy usually has a short period of symptoms (acute). Symptoms usually include severe headache, paralysis of eye muscles, visual disturbances, nausea, and vomiting.[10]

Physical Examination

Patients with pituitary apoplexy appear ill and usually look tired. Physical examination of patients with pituitary apoplexy is usually remarkable for orthostatic hypotension, visual acuity and visual field defects, cranial nerve palsies, Horner syndrome, meningeal irritation, altered level of consciousness, severe mental status change, and other signs of hypopituitarism.

Laboratory Findings

Laboratory findings consistent with the diagnosis of pituitary apoplexy include endocrinopathies from hypofunction of the pituitary gland. Blood tests will be done to check levels of ACTH, cholesterol, cortisol, growth hormone, LH, prolactin and somatomedin C (IGF-1).

X-ray

X-ray is an inexpensive method for evaluating pituitary apoplexy. However, x-ray is neither the best initial test, nor the most accurate test in evaluating pituitary apoplexy.

CT

CT scan without contrast is the initial test of choice in emergency department patients who present with sudden-onset severe headache, visual loss or ophthalmoplegia suggestive of pituitary apoplexy. A CT scan can also help to differentiate whether subarachnoid hemorrhage is arising from pituitary hemorrhage or an aneurysm.

MRI

MRI is done if the CT scan is suspicious for pituitary apoplexy. MRI is more sensitive than CT scan. MRI is more accurate in distinguishing the soft tissues of the pituitary from the surrounding bony structures. MRI is also superior to CT scan for detecting ischemia and infarction in brain tissue.

Ultrasound

There are no ultrasound findings associated with pituitary apoplexy.

Other Imaging Findings

There are no other imaging findings associated with pituitary apoplexy.

Other Diagnostic Studies

There are no other diagnostic studies associated with pituitary apoplexy.

Treatment

The optimal therapy for pituitary apoplexy depends upon presentation of the patient. The emphasis is on early hemodynamic stabilization of the patient, with evaluation for signs of deficiency of pituitary hormones. Life threatening hypopituitarism must be treated with replacement of hormones.

Surgery

Neurological decompression is done once the patient is hemodynamically stable. Surgery relieves pressure on the pituitary and improves visual field defects and ocular palsy. Early decompression has been associated with better visual and endocrine outcome.

References

  1. Semple, Patrick L.; Webb, Michael K.; de Villiers, Jacques C.; Laws, Edward R. (2005). “Pituitary Apoplexy”. Neurosurgery. 56 (1): 65–73. doi:10.1227/01.NEU.0000144840.55247.38. ISSN 0148-396X.
  2. Zayour DH, Selman WR, Arafah BM (2004). “Extreme elevation of intrasellar pressure in patients with pituitary tumor apoplexy: relation to pituitary function”. J Clin Endocrinol Metab. 89 (11): 5649–54. doi:10.1210/jc.2004-0884. PMID 15531524.
  3. BROUGHAM M, HEUSNER AP, ADAMS RD (1950). “Acute degenerative changes in adenomas of the pituitary body–with special reference to pituitary apoplexy”. J. Neurosurg. 7 (5): 421–39. doi:10.3171/jns.1950.7.5.0421. PMID 14774761.
  4. Rapalino O, Mullins ME (2017). “Intracranial Infectious and Inflammatory Diseases Presenting as Neurosurgical Pathologies”. Neurosurgery. doi:10.1093/neuros/nyx201. PMID 28575459.
  5. Konakondla S, Schirmer CM, Li F, Geng X, Ding Y (2017). “New Developments in the Pathophysiology, Workup, and Diagnosis of Dural Venous Sinus Thrombosis (DVST) and a Systematic Review of Endovascular Treatments”. Aging Dis. 8 (2): 136–148. doi:10.14336/AD.2016.0915. PMC 5362174. PMID 28400981.
  6. Yadav P, Bradley AL, Smith JH (2017). “Recognition of Chronic Migraine by Medicine Trainees: A Cross-Sectional Survey”. Headache. doi:10.1111/head.13133. PMID 28653369.
  7. Fernandez A, Karavitaki N, Wass JA (2010). “Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK)”. Clin Endocrinol (Oxf). 72 (3): 377–82. doi:10.1111/j.1365-2265.2009.03667.x. PMID 19650784.
  8. Briet C, Salenave S, Bonneville JF, Laws ER, Chanson P (2015). “Pituitary Apoplexy”. Endocr. Rev. 36 (6): 622–45. doi:10.1210/er.2015-1042. PMID 26414232.
  9. Woo HJ, Hwang JH, Hwang SK, Park YM (2010). “Clinical outcome of cranial neuropathy in patients with pituitary apoplexy”. J Korean Neurosurg Soc. 48 (3): 213–8. doi:10.3340/jkns.2010.48.3.213. PMC 2966721. PMID 21082047.
  10. Pyrgelis ES, Mavridis I, Meliou M (2017). “Presenting Symptoms of Pituitary Apoplexy”. J Neurol Surg A Cent Eur Neurosurg. doi:10.1055/s-0037-1599051. PMID 28437813.

Template:WH Template:WS

Historical Perspective

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Akshun Kalia M.B.B.S.[2]

Overview

Pituitary apoplexy was first discovered by Pearce Bailey in the year 1898. In 1905, Leopold Bleibtreu recorded the postmortem examination of a 21-year-old acromegalic patient, in whom he discovered that the pituitary gland had been replaced by an old hemorrhage. The term pituitary apoplexy was coined by Brougham, Heusner, and Adams in 1950.

Historical perspective

Discovery

  • In 1898, Pearce Bailey, an American neurologist, discovered pituitary apoplexy.
  • In 1905, Leopold Bleibtreu, a German physicist, performed the first postmortem examination on a patient with pituitary apoplexy.
  • In 1950, Brougham, Heusner, and Adams from the Boston City Hospital and Harvard Medical School coined the term “pituitary apoplexy”.[1]

Landmark Events in the Development of Treatment Strategies

  • In 1925, the first surgery for pituitary apoplexy was performed.

References

  1. BROUGHAM M, HEUSNER AP, ADAMS RD (1950). “Acute degenerative changes in adenomas of the pituitary body–with special reference to pituitary apoplexy”. J. Neurosurg. 7 (5): 421–39. doi:10.3171/jns.1950.7.5.0421. PMID 14774761.

Template:WH Template:WS

Pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Akshun Kalia M.B.B.S.[2]

Overview

Pituitary apoplexy is an acute clinical syndrome caused by hemorrhage and necrosis in the pituitary gland. Most commonly, pituitary apoplexy is associated with pituitary adenoma. Pituitary adenoma predisposes the patient to an increased risk of bleeding within the pituitary gland. Pituitary adenoma has fenestrated endothelium surrounded by a variable number of smooth muscle cells which are not found in the normal pituitary gland, leading to increased susceptibility to pituitary apoplexy in these tumors. Pituitary apoplexy can result from a mutation in AIP gene which is a tumor suppressor gene located on chromosome 11q13.2. On gross pathology, pituitary apoplexy presents with hemorrhage with or without necrosis. Electron microscopy shows evidence of abnormal fenestration of tumor vessels (pituitary adenoma) with fragmented basal membranes that may predispose the patient to hemorrhage.

Pathophysiology

Pituitary apoplexy is caused by bleeding into the pituitary gland. Most often, pituitary apoplexy is seen with a pituitary adenoma. Pituitary adenoma predisposes the patient to an increased risk of bleeding within the pituitary gland.[1][2][3][4][5][6][7][8]

Genetics

Associated Conditions

Pituitary apoplexy is seen with 0.6 to 10% of pituitary adenomas.

Gross Pathology

  • The predominant finding is hemorrhage with or without necrosis.
  • Pale, necrotic material is particularly found when there is a long interval between the acute clinical event and surgery.

Microscopic Pathology

Electron microscopic shows evidence of abnormal fenestration of tumor vessels (pituitary adenoma) with fragmented basal membranes that may predispose the patient to hemorrhage.

Histopathological image of nonfunctioning pituitary adenoma. Hematoxylin & eosin stain showing basophilic appearance of the cells.
Histopathological image of nonfunctioning pituitary adenoma. Hematoxylin & eosin stain showing basophilic appearance of the cells. Source: By Jensflorian (Own work) [CC BY-SA 3.0 (http://creativecommons.org/licenses/by-sa/3.0)], via Wikimedia Commons

References

  1. Nielsen EH, Lindholm J, Bjerre P, Christiansen JS, Hagen C, Juul S, Jørgensen J, Kruse A, Laurberg P (2006). “Frequent occurrence of pituitary apoplexy in patients with non-functioning pituitary adenoma”. Clin. Endocrinol. (Oxf). 64 (3): 319–22. doi:10.1111/j.1365-2265.2006.02463.x. PMID 16487443.
  2. Chacko AG, Chacko G, Seshadri MS, Chandy MJ (2002). “Hemorrhagic necrosis of pituitary adenomas”. Neurol India. 50 (4): 490–3. PMID 12577104.
  3. Zayour DH, Selman WR, Arafah BM (2004). “Extreme elevation of intrasellar pressure in patients with pituitary tumor apoplexy: relation to pituitary function”. J Clin Endocrinol Metab. 89 (11): 5649–54. doi:10.1210/jc.2004-0884. PMID 15531524.
  4. Oldfield EH, Merrill MJ (2015). “Apoplexy of pituitary adenomas: the perfect storm”. J Neurosurg. 122 (6): 1444–9. doi:10.3171/2014.10.JNS141720. PMID 25859802.
  5. Schechter J (1972). “Ultrastructural changes in the capillary bed of human pituitary tumors”. Am J Pathol. 67 (1): 109–26. PMC 2032586. PMID 5055626.
  6. Schechter J, Goldsmith P, Wilson C, Weiner R (1988). “Morphological evidence for the presence of arteries in human prolactinomas”. J Clin Endocrinol Metab. 67 (4): 713–9. doi:10.1210/jcem-67-4-713. PMID 3417848.
  7. Nawar RN, AbdelMannan D, Selman WR, Arafah BM (2008). “Pituitary tumor apoplexy: a review”. J Intensive Care Med. 23 (2): 75–90. doi:10.1177/0885066607312992. PMID 18372348.
  8. Findling JW, Tyrrell JB, Aron DC, Fitzgerald PA, Wilson CB, Forsham PH (1981). “Silent pituitary apoplexy: subclinical infarction of an adrenocorticotropin-producing pituitary adenoma”. J. Clin. Endocrinol. Metab. 52 (1): 95–7. doi:10.1210/jcem-52-1-95. PMID 6256408.

Template:WH Template:WS

Causes

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Akshun Kalia M.B.B.S.[2]

Overview

Pituitary apoplexy is most commonly caused by bleeding into the pituitary gland from a benign tumor of the pituitary. When this bleeding occurs in a woman during or immediately after childbirth, it is called Sheehan syndrome. Other conditions causing pituitary apoplexy are coagulopathy, major surgery, hypertension, drugs such as dopamine receptor agonists, GnRH agonists, antiplatelets, and thrombolytic therapy.

Causes

Common causes

The most common cause of pituitary apoplexy is pituitary adenoma (a benign tumor of pituitary gland). Other common causes include:[1][2][3][4]

Less common causes

References

  1. Baruah, ManashP; Ranabir, Salam (2011). “Pituitary apoplexy”. Indian Journal of Endocrinology and Metabolism. 15 (7): 188. doi:10.4103/2230-8210.84862. ISSN 2230-8210.
  2. Cooper DM, Bazaral MG, Furlan AJ, Sevilla E, Ghattas MA, Sheeler LR, Little JR, Hahn JF, Sheldon WC, Loop FD (1986). “Pituitary apoplexy: a complication of cardiac surgery”. Ann. Thorac. Surg. 41 (5): 547–50. PMID 3486645.
  3. Rajasekaran S, Vanderpump M, Baldeweg S, Drake W, Reddy N, Lanyon M, Markey A, Plant G, Powell M, Sinha S, Wass J (2011). “UK guidelines for the management of pituitary apoplexy”. Clin. Endocrinol. (Oxf). 74 (1): 9–20. doi:10.1111/j.1365-2265.2010.03913.x. PMID 21044119.
  4. Goel A, Deogaonkar M, Desai K (1995). “Fatal postoperative ‘pituitary apoplexy’: its cause and management”. Br J Neurosurg. 9 (1): 37–40. PMID 7786424.

Template:WH Template:WS

Differentiating Pituitary apoplexy from other Diseases

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Akshun Kalia M.B.B.S.[2]

Overview

Pituitary apoplexy must be differentiated from other diseases that cause severe headache such as subarachnoid hemorrhage, meningitis, intracranial mass, cerebral hemorrhage, cerebral infarction, intracranial venous thrombosis, migraine, head injury, and lymphocytic hypophysitis.

Differentiating Pituitary apoplexy From Other Diseases

Pituitary apoplexy should be differentiated from other diseases causing severe headache for example: [1][2][3][4][5][6][7][8][9][10][11]

Onset Disease Symptoms Gold Standard Test CT/MRI Findings Other Investigation Findings
Headache Characteristics Associated Features
Sudden Pituitary apoplexy Severe headache MRI Blood tests may be done to check:
Subarachnoid hemorrhage Digital subtraction angiography
Meningitis Headache is associated with: Lumbar puncture for CSF
Cerebral hemorrhage Rapidly progressing headache CT without contrast

(differentiates ischemic stroke from hemorrhagic stroke)

Migraine
  • Severe to moderate headache
  • One-sided
  • Pulsating
  • Lasts between several hours to three days
  • CT and MRI may be needed to rule out other suspected possible causes of headache
Head injury (Epidural hematoma)
  • Dull
  • Throbbing
  • One sided or all around
CT scan without contrast
Lymphocytic hypophysitis Pituitary biopsy CT & MRI typically reveal features of a pituitary mass
Gradual Intracranial mass Morning headache MRI
  • CT or MRI is the initial test to detect intracranial lesions (ring enhancing lesions)
  • These imaging tests determine the location of intracranial mass lesion(s) and help in guiding therapy
Intracranial venous thrombosis Digital subtraction angiography



Pituitary apoplexy should be differentiated from other diseases causing hypopituitarism.[10][12][13][14][15][16][17]

Diseases Onset Manifestations Diagnosis
History and Symptoms Physical examination Laboratory findings Gold standard Imaging Other investigation findings
Traumatic delivery Lactation failure Menstrual irregularities Other features
Sheehan’s syndrome Acute ++ ++ Oligo/amenorrhea Symptoms of:
  • Clinical diagnosis
  • Most senitive test: Low baseline prolactin levels w/o response to TRH
CT/MRI:
  • Sequential changes of pituitary enlargement followed by:
  • Shrinkage and necrosis leading to decreased sellar volume or empty sella
Lymphocytic hypophysitis Acute +/- + Oligo/amenorrhea Assays for:
  • Anti-TPO
  • Anti-Tg Ab
Pituitary apoplexy Acute +/- ++ Oligo/amenorrhea
  • Decreased levels of anterior pituitary hormones in blood.
  • CT scan without contrast: Hemorrhage on CT presents as a hyperdense lesion
  • MRI: If inconclusive CT

Blood tests may be done to check:

Empty sella syndrome Chronic + Oligo/amenorrhea
  • Decreased levels of pituitary hormones in blood.
Simmonds’ disease/Pituitary cachexia Chronic +/- + Oligo/amenorrhea
  • Decreased levels of anterior pituitary hormones in blood.
  • Done to rule out any pituitary cause
Hypothyroidism Chronic +/- Oligomenorrhea/menorrhagia
  • Low T3,T4
  • Normal/ low TSH
  • Rest of pituitary hormone levels WNL
  • Done to rule out any pituitary cause
  • Assays for anti-TPO and anti-Tg Ab
  • FNA biopsy
Hypogonadotropic hypogonadism Chronic Oligo/amenorrhea
  • Done to rule out any pituitary cause
Hypoprolactinemia Chronic +
  • Puerperal agalactogenesis
  • No workup is necessary
  • Decreased prolactin levels
  • Done to rule out any pituitary cause
Panhypopituitarism Chronic + Oligo/amenorrhea
  • All pituitary hormones decreased
  • Done to rule out any pituitary cause
Primary adrenal insufficiency/Addison’s disease Chronic
  • Abdominal CT
  • Abdominal CT
Menopause Chronic +/- Oligo/amenorrhea Normal

References

  1. Endrit Ziu & Fassil Mesfin (2017). “Subarachnoid Hemorrhage”. PMID 28722987.
  2. Benedikt Schwermer, Daniel Eschle & Constantine Bloch-Infanger (2017). “[Fever and Headache after a Vacation in Thailand]”. Deutsche medizinische Wochenschrift (1946). 142 (14): 1063–1066. doi:10.1055/s-0043-106282. PMID 28728201.
  3. Otto Rapalino & Mark E. Mullins (2017). “Intracranial Infectious and Inflammatory Diseases Presenting as Neurosurgical Pathologies”. Neurosurgery. doi:10.1093/neuros/nyx201. PMID 28575459.
  4. I. B. Komarova, V. P. Zykov, L. V. Ushakova, E. K. Nazarova, E. B. Novikova, O. V. Shuleshko & M. G. Samigulina (2017). “[Clinical and neuroimaging signs of cardioembolic stroke laboratory in children]”. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 117 (3. Vyp. 2): 11–19. doi:10.17116/jnevro20171173211-19. PMID 28665364.
  5. Sanjay Konakondla, Clemens M. Schirmer, Fengwu Li, Xiaogun Geng & Yuchuan Ding (2017). “New Developments in the Pathophysiology, Workup, and Diagnosis of Dural Venous Sinus Thrombosis (DVST) and a Systematic Review of Endovascular Treatments”. Aging and disease. 8 (2): 136–148. doi:10.14336/AD.2016.0915. PMID 28400981.
  6. Priyanka Yadav, Alec L. Bradley & Jonathan H. Smith (2017). “Recognition of Chronic Migraine by Medicine Trainees: A Cross-Sectional Survey”. Headache. doi:10.1111/head.13133. PMID 28653369.
  7. S. Wulffeld, L. S. Rasmussen, B. Hojlund Bech & J. Steinmetz (2017). “The effect of CT scanners in the trauma room – an observational study”. Acta anaesthesiologica Scandinavica. 61 (7): 832–840. doi:10.1111/aas.12927. PMID 28635146.
  8. Johnston PC, Chew LS, Hamrahian AH, Kennedy L (2015). “Lymphocytic infundibulo-neurohypophysitis: a clinical overview”. Endocrine. 50 (3): 531–6. doi:10.1007/s12020-015-0707-6. PMID 26219407.
  9. Makale MT, McDonald CR, Hattangadi-Gluth JA, Kesari S (2017). “Mechanisms of radiotherapy-associated cognitive disability in patients with brain tumours”. Nat Rev Neurol. 13 (1): 52–64. doi:10.1038/nrneurol.2016.185. PMID 27982041.
  10. 10.0 10.1 Sato N, Sze G, Endo K (1998). “Hypophysitis: endocrinologic and dynamic MR findings”. AJNR Am J Neuroradiol. 19 (3): 439–44. PMID 9541295.
  11. Kidwell CS, Saver JL, Villablanca JP, Duckwiler G, Fredieu A, Gough K, Leary MC, Starkman S, Gobin YP, Jahan R, Vespa P, Liebeskind DS, Alger JR, Vinuela F (2002). “Magnetic resonance imaging detection of microbleeds before thrombolysis: an emerging application”. Stroke. 33 (1): 95–8. PMID 11779895.
  12. Powrie JK, Powell M, Ayers AB, Lowy C, Sönksen PH (1995). “Lymphocytic adenohypophysitis: magnetic resonance imaging features of two new cases and a review of the literature”. Clin. Endocrinol. (Oxf). 42 (3): 315–22. PMID 7758238.
  13. Honegger J, Schlaffer S, Menzel C, Droste M, Werner S, Elbelt U, Strasburger C, Störmann S, Küppers A, Streetz-van der Werf C, Deutschbein T, Stieg M, Rotermund R, Milian M, Petersenn S (2015). “Diagnosis of Primary Hypophysitis in Germany”. J. Clin. Endocrinol. Metab. 100 (10): 3841–9. doi:10.1210/jc.2015-2152. PMID 26262437.
  14. Thodou E, Asa SL, Kontogeorgos G, Kovacs K, Horvath E, Ezzat S (1995). “Clinical case seminar: lymphocytic hypophysitis: clinicopathological findings”. J. Clin. Endocrinol. Metab. 80 (8): 2302–11. doi:10.1210/jcem.80.8.7629223. PMID 7629223.
  15. Imura H, Nakao K, Shimatsu A, Ogawa Y, Sando T, Fujisawa I, Yamabe H (1993). “Lymphocytic infundibuloneurohypophysitis as a cause of central diabetes insipidus”. N. Engl. J. Med. 329 (10): 683–9. doi:10.1056/NEJM199309023291002. PMID 8345854.
  16. Hsieh CY, Liu BY, Yang YN, Yin WH, Young MS (2011). “Massive pericardial effusion with diastolic right ventricular compression secondary to hypothyroidism in a 73-year-old woman”. Emerg Med Australas. 23 (3): 372–5. doi:10.1111/j.1742-6723.2011.01425.x. PMID 21668725.
  17. Dejager S, Gerber S, Foubert L, Turpin G (1998). “Sheehan’s syndrome: differential diagnosis in the acute phase”. J. Intern. Med. 244 (3): 261–6. PMID 9747750.

Template:WH Template:WS

Epidemiology and Demographics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Akshun Kalia M.B.B.S.[2]

Overview

The worldwide prevalence of pituitary apoplexy is 6.2 per 100,000 persons. The incidence of pituitary apoplexy is 0.7 per 100,000 persons.[1]

Epidemiology and Demographics

Prevalence

  • Worldwide, the prevalence of pituitary apoplexy is 6.2 per 100,000 persons.[1]

Incidence

  • Worldwide, the incidence of pituitary apoplexy is 0.7 per 100,000 persons.[2]

Age

  • Pituitary apoplexy is commonly seen in adults with a mean age of 57 years.

Gender

  • Males are more commonly affected with pituitary apoplexy than females. Two-thirds of all patients are male.

References

  1. 1.0 1.1 Fernandez A, Karavitaki N, Wass JA (2010). “Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK)”. Clin Endocrinol (Oxf). 72 (3): 377–82. doi:10.1111/j.1365-2265.2009.03667.x. PMID 19650784.
  2. Raappana A, Koivukangas J, Ebeling T, Pirilä T (2010). “Incidence of pituitary adenomas in Northern Finland in 1992-2007”. J Clin Endocrinol Metab. 95 (9): 4268–75. doi:10.1210/jc.2010-0537. PMID 20534753.

Template:WH Template:WS

Risk Factors

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief: Akshun Kalia M.B.B.S.[2]

Overview

Common risk factors in the development of pituitary apoplexy include bleeding disorders, diabetes, use of a breathing machine, radiation to the pituitary gland, angiography, head injury, surgery, pituitary stimulation, and pregnancy induced lactotroph hyperplasia.

Risk Factors

Common risk factors in the development of pituitary apoplexy include:[1][2]

References

  1. Briet C, Salenave S, Bonneville JF, Laws ER, Chanson P (2015). “Pituitary Apoplexy”. Endocr. Rev. 36 (6): 622–45. doi:10.1210/er.2015-1042. PMID 26414232.
  2. Wakai S, Fukushima T, Teramoto A, Sano K (1981). “Pituitary apoplexy: its incidence and clinical significance”. J Neurosurg. 55 (2): 187–93. doi:10.3171/jns.1981.55.2.0187. PMID 7252541.

Template:WH Template:WS

Natural History, Complications and Prognosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Akshun Kalia M.B.B.S.[2]

Overview

If left untreated, pituitary apoplexy can be an acute life threatening condition. Pituitary apoplexy may lead to a sudden decline in pituitary hormone production. The most life threatening endocrinopathy is an acute adrenal crisis. Complications of pituitary apoplexy include vision loss, optic neuritis, diplopia, ptosis, increased intracranial pressure, hypothyroidism, hypogonadism, and growth hormone deficiency. The prognosis of pituitary apoplexy depends upon presentation and initiation of therapy. Emergent application of medical and surgical treatment is associated with greater improvement in visual field defects, visual acuity, and diplopia. The outlook is good for people who are diagnosed early and treated. Patients require hormone(s) replacement therapy for life.

Natural History

If left untreated, pituitary apoplexy features depend upon the size of hemorrhage. Pituitary apoplexy is an acute life threatening condition in case of massive hemorrhage. Pituitary apoplexy may lead to a sudden decline in pituitary hormone production. The most life threatening endocrinopathy is an acute adrenal crisis. In a case of small sized hemorrhage, pituitary apoplexy may result in some temporary or permanent endocrinopathies from hypofunction of the pituitary gland.[1][2]

Complications

Complications of pituitary apoplexy can include:

Prognosis

  • Acute pituitary apoplexy can be life-threatening.
  • The mortality rate associated with pituitary apoplexy is 12.5% and without treatment, the mortality rate can reach as high as 50%.
  • Emergent application of medical and surgical treatment is associated with greater improvement in visual field defects, visual acuity, and diplopia.
  • Prognosis is good for people who are diagnosed early and treated. Patients require hormone(s) replacement therapy for life.[3][4][5][6]

References

  1. Woo HJ, Hwang JH, Hwang SK, Park YM (2010). “Clinical outcome of cranial neuropathy in patients with pituitary apoplexy”. J Korean Neurosurg Soc. 48 (3): 213–8. doi:10.3340/jkns.2010.48.3.213. PMC 2966721. PMID 21082047.
  2. Baruah, ManashP; Ranabir, Salam (2011). “Pituitary apoplexy”. Indian Journal of Endocrinology and Metabolism. 15 (7): 188. doi:10.4103/2230-8210.84862. ISSN 2230-8210.
  3. Xiao D, Wang S, Huang Y, Zhao L, Wei L, Ding C (2015). “Clinical analysis of infarction in pituitary adenoma”. Int J Clin Exp Med. 8 (5): 7477–86. PMC 4509236. PMID 26221291.
  4. Nawar RN, AbdelMannan D, Selman WR, Arafah BM (2008). “Pituitary tumor apoplexy: a review”. J Intensive Care Med. 23 (2): 75–90. doi:10.1177/0885066607312992. PMID 18372348.
  5. Randeva HS, Schoebel J, Byrne J, Esiri M, Adams CB, Wass JA (1999). “Classical pituitary apoplexy: clinical features, management and outcome”. Clin. Endocrinol. (Oxf). 51 (2): 181–8. PMID 10468988.
  6. Murad-Kejbou S, Eggenberger E (2009). “Pituitary apoplexy: evaluation, management, and prognosis”. Curr Opin Ophthalmol. 20 (6): 456–61. doi:10.1097/ICU.0b013e3283319061. PMID 19809320.

Template:WH Template:WS

Diagnosis

Diagnosis

History and Symptoms | Physical Examination | Laboratory Findings | CT | MRI | Other Imaging Findings | Other Diagnostic Studies

Treatment

Treatment

Medical Therapy | Surgery | Cost-Effectiveness of Therapy | Future or Investigational Therapies

Case Studies

Case Studies

Case #1

Template:WH Template:WS

Looking for the patient version?

Back to the patient-friendly article

© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH